ES-3000 / Escend Pharma - LARVOL DELTA

Escend Announces Poster Presentation at the Annual Meeting of the European Hematology Association (EHS) from an Investigator-Initiated Phase I/II study evaluating ES-3000 in Myelodysplastic Syndrome (MDS) (PRNewswire) - "Escend Pharmaceuticals, Inc., a privately held oncology company, announced today a poster presentation with initial data from the Australasian Leukaemia and Lymphoma Group's (ALLG) investigator-initiated Phase I/II platform study (MYDAS-T MDS05 domain 1) evaluating ES-3000 alone and in combination with ASTX727 at European Hematology Association (EHS) in Madrid, Spain...The results indicate a response in 40% of evaluable patients who received ES-3000 as a single agent. The dose-limiting toxicities as per BION modeling allowed the study to dose escalate."

P1/2 data • Hematological Malignancies • Myelodysplastic Syndrome • Oncology

A dose determining trial to assess the recommended dose of ES-3000 and ASTX727 for patients with Myelodysplasia (ANZCTR) - P1/2 | N=32 | Recruiting | Sponsor: Australasian Leukaemia and Lymphoma Group | Not yet recruiting ➔ Recruiting

Enrollment open • Myelodysplastic Syndrome

Escend Pharmaceuticals, Inc., Receives IND Clearance from the FDA for ES-3000 Phase I Study in Relapsed or Refractory Acute Myeloid Leukemia (AML) (PRNewswire) - "Escend Pharmaceuticals, Inc...announced today that the United States Food and Drug Administration (FDA) has cleared its investigational new drug (IND) application for its lead drug candidate, ES-3000 for a Phase I clinical trial in relapsed or refractory (R/R) acute myeloid leukemia (AML). The primary aim of the Phase I study is to determine the safety and tolerability of ES-3000 in subjects with R/R AML."

IND • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Oncology